Beta Finch - S&P 100 - EN

# Beta Finch Podcast Script: Palantir Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and joining me as always is Jordan. Today we're diving into Palantir's absolutely explosive Q1 2026 results - and folks, when I say explosive, I mean it. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Alex, I've been covering earnings for years, and these Palantir numbers are just wild. We're talking about 85% year-over-year revenue growth - their highest as a public company. But what really caught my eye was their U.S. business hitting triple digits for the first time since their direct listing.

**ALEX:** Right, 104% growth in the U.S.! And get this - their U.S. business now represents 79% of total revenue. They pulled in $1.63 billion in revenue for the quarter, up 16% sequentially. But Jordan, what's your take on their "Rule of 40" score hitting 145?

**JORDAN:** For listeners who might not know, the Rule of 40 combines revenue growth rate and profit margins - and anything over 40 is considered excellent. Palantir just scored 145, up from 127 last quarter. That's not just good, that's almost unheard of at this scale.

**ALEX:** And they're not slowing down. They raised their full-year 2026 revenue guidance to $7.656 billion - that's 71% growth year-over-year and a 10% bump from their previous guidance. What's driving all this growth?

**JORDAN:** It's all about their AIP platform - their Artificial Intelligence Platform. CEO Alex Karp was pretty bold on the call, claiming "almost every single highlighted example of AI that actually is producing results in the U.S. is actually Palantir." That's a huge statement, but the numbers seem to back it up.

**ALEX:** Speaking of bold statements, Karp mentioned they're achieving this growth with essentially just seven salespeople who actually sell, compared to what would normally be 7,000 for a company their size. That suggests incredible product-market fit.

**JORDAN:** The enterprise AI story is fascinating here. While everyone's talking about AI "slop" - their term for unreliable AI outputs - Palantir positions their platform as the "no-slop zone." They're saying enterprises need precision and governance when deploying AI, not just flashy demos.

**ALEX:** Let's break down the segments. Their commercial business grew 95% year-over-year to $774 million, with U.S. commercial specifically up 133%. But government wasn't slouch either - up 76% to $858 million.

**JORDAN:** The government wins are particularly interesting. They landed a $300 million USDA contract and their Maven Smart System for defense continues expanding. Ryan Taylor mentioned that Maven usage has doubled in the past four months and is now 4x what it was twelve months ago.

**ALEX:** What struck me was their customer expansion. Net dollar retention hit 150% - that means existing customers are spending 50% more than they were a year ago. And they're now at 1,007 total customers, up 31% year-over-year.

**JORDAN:** The cash generation is incredible too. They generated $899 million in cash from operations and $925 million in adjusted free cash flow. Karp made a great point - their free cash flow this quarter is larger than their total revenue was in the same quarter last year.

**ALEX:** During the Q&A, there were some interesting exchanges about competition from AI labs like OpenAI and Anthropic moving into enterprise. How did management respond to that?

**JORDAN:** Karp was pretty dismissive, honestly. He basically said "go ahead and try the alternatives" - test out what he calls the "slop" and then compare it to what Palantir delivers. He seems confident that enterprises doing real-world testing will come back to Palantir.

**ALEX:** CTO Shyam Sankar made a fascinatin

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Exxon Mobil's Q1 2026 earnings call - and wow, what a quarter to unpack. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And right off the bat, we need to address the elephant in the room - this earnings call was dominated by the ongoing Middle East conflict and its impact on global energy markets. CEO Darren Woods opened with some pretty sobering commentary about the situation.

**ALEX**: Absolutely. Woods was very direct about the human cost first, mentioning their colleagues and partners living under daily threats in the region. But from a business perspective, Jordan, the disruption has actually highlighted Exxon's competitive advantages in a major way.

**JORDAN**: Exactly. What struck me was how Woods framed this as essentially a stress test for all the changes they've made over the past decade. And by most measures, they seem to have passed with flying colors. Despite what he called "unprecedented disruption in the world supply of oil and natural gas," they maintained deliveries globally and even ramped up refining production by 200,000 barrels per day from February to March.

**ALEX**: That's like adding a mid-sized refinery overnight! And the financial results reflect this operational excellence. Even excluding timing effects and identified items, their first-quarter earnings per share were up versus 2025. CFO Kathy Mikells highlighted that their Energy Products segment made $2.8 billion in the quarter - that's up $2 billion from last year.

**JORDAN**: The refining story is particularly compelling. Remember when Exxon announced that Beaumont refinery expansion back in 2023? There were lots of questions about whether refining investments made sense. Well, Woods announced that expansion has already fully recovered its initial investment - ahead of expectations.

**ALEX**: And they're not just benefiting from higher margins - they're creating structural advantages. Their Gulf Coast refineries ran at record utilization rates, and they've got this global supply chain organization that rapidly executed alternate routings from the US Gulf Coast to Asia. It's that scale and integration advantage Woods keeps talking about.

**JORDAN**: Speaking of scale advantages, let's talk about their growth engines. In Guyana, they hit record production levels again and have three new projects under construction. The Oahu project expects first oil late this year. But what I found interesting was their $100 million commitment over ten years for STEM education in Guyana - that's the kind of long-term relationship building that creates sustainable competitive advantages.

**ALEX**: And in the Permian, they're still on track for 1.8 million oil-equivalent barrels this year, with that longer-term target of 2.5 million. What's interesting is Woods' confidence that they're not seeing any plateau in opportunities there, unlike some competitors who've predicted resource constraints.

**JORDAN**: The LNG story is fascinating too. Golden Pass achieved first LNG in March - that's about a 5% increase in US LNG exports. And by the time all three trains are online, they'll increase current US exports by roughly 15%. But here's what's really notable - with the Middle East disruptions, that "long" LNG market everyone was predicting has essentially disappeared overnight.

**ALEX**: Right, and they've got Papua New Guinea and Mozambique LNG projects expecting final investment decisions later this year. Woods was pretty confident about their positioning in what's now a much tighter LNG market.

**JORDAN**: Let's dive into some of the Q&A highlights, because

This episode includes AI-generated content.

# Beta Finch Podcast Script - Linde Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the numbers that matter. I'm Alex, and joining me as always is Jordan. Today we're unpacking Linde's Q1 2026 results - the industrial gas giant that just delivered another solid quarter despite some serious global headwinds.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And wow, what a quarter to analyze. Linde really showed why they're considered the gold standard in industrial gases. EPS of $4.33 was up 10% year-over-year, with operating margins hitting that impressive 30% mark. When you've got geopolitical chaos, supply chain disruptions, and economic uncertainty swirling around, delivering those kinds of numbers is no small feat.

**ALEX:** Absolutely. And let's talk about that revenue picture - $8.8 billion in sales, up 8% year-over-year. But here's what I found interesting, Jordan: when you strip out the 5% currency tailwind and 1% from acquisitions, underlying sales growth was a more modest 3%. That tells us the real story is about pricing discipline rather than volume explosions.

**JORDAN:** Exactly right, Alex. CEO Matthew White was pretty clear about this during the call - they're seeing 2% higher pricing and just 1% volume growth. And when you dig into the geographic breakdown, it's really a tale of three regions. The Americas are firing on all cylinders with base volume growth, APAC is holding steady thanks to project startups, but EMEA? That's where the weakness is concentrated.

**ALEX:** The EMEA situation is fascinating from a macro perspective. White mentioned they're seeing production shifting away from Continental Europe to more feedstock-advantaged assets in the Americas. He basically said if your feedstock comes on a ship, you're in trouble right now, but if it's pipeline or rail-based, you're in a better position.

**JORDAN:** And that brings us to one of the most interesting parts of this call - helium. I mean, who would have thought helium would be such a hot topic on an earnings call? But with the Middle East conflict disrupting supply chains, Linde is sitting pretty with their diversified sourcing. They're about 85-90% contracted on helium, and White said they're already securing new long-term agreements rather than chasing spot market gains.

**ALEX:** Smart strategy there. But let's talk about the real growth engine everyone's buzzing about - commercial space. This is where it gets exciting, Jordan. Linde mentioned they're investing over $1 billion in ultra-high-purity plants for advanced semiconductor fabs, and the space business is growing so fast they might break it out as a separate segment when it hits 5% of sales.

**JORDAN:** The math on that is pretty striking, Alex. Five percent of sales would be about $1.7 billion annually. White mentioned they previously thought space might hit $1 billion by decade's end, but now they're talking about potentially reaching $1.7 billion. That's not just growth - that's explosive growth in a completely new market.

**ALEX:** And the drivers make sense. It's all about launch frequency, rocket size, and propellant type. Linde supplies oxygen for oxidizer and nitrogen for densification, plus hydrogen for hydrogen-fueled rockets. With companies racing to build satellite constellations and the entire commercial space economy taking off, Linde is positioned right in the sweet spot.

**JORDAN:** Now let's address the elephant in the room - guidance. For Q2, they're guiding $4.40 to $4.50 EPS, which is 8-10% growth. Full year guidance is $17.60 to $17.90, representing 7-9% growth. Here's what I find notable: they raised the bottom of the range by 20 cent

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into Chevron's Q1 2026 earnings call. Now, before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter to analyze! Chevron just reported some really solid numbers despite operating in what can only be described as a pretty chaotic global environment.

**ALEX:** Absolutely. Let's start with the headline numbers. Chevron posted $2.2 billion in earnings, or $1.11 per share. But the adjusted earnings tell a cleaner story - $2.8 billion or $1.41 per share. Jordan, what stood out to you in these results?

**JORDAN:** Well, the big story here is how Chevron's integrated model really shined during market volatility. They had about $3 billion in unfavorable timing effects due to steep commodity price rises in March, but management was clear this was largely paper positions that would unwind. What's impressive is how they navigated supply disruptions.

**ALEX:** Right, and CEO Michael Wirth really emphasized this integration advantage. They're now running over 40% equity crude in their Asian refineries - compared to their historical 15% across the system. That's a massive operational shift.

**JORDAN:** Exactly. In the U.S., they're above 50% equity crude throughput at some refineries. This isn't just about margins - it's about supply security. When global energy markets are tight, having your own crude to feed your own refineries is like having a strategic ace up your sleeve.

**ALEX:** Let's talk about the geopolitical elephant in the room. There's clearly some major conflict affecting Middle Eastern energy supplies, though the transcript doesn't specify exactly what. How is Chevron positioned?

**JORDAN:** Interestingly, Chevron seems relatively insulated. Less than 5% of their portfolio is in the Middle East region. But they're definitely benefiting from the market dynamics. Their Australian LNG facilities are running at full capacity, and they just sold their first U.S. LNG cargo into Europe - talk about good timing.

**ALEX:** And the production numbers are strong across the board. They're reaffirming 7-10% production growth for the year, with U.S. production over 2 million barrels per day. The TCO project in Kazakhstan is back above 1 million barrels per day after some earlier disruptions.

**JORDAN:** What I found fascinating was the Venezuela update. They've expanded their position there through an asset swap with PDVSA, increasing their stake in Petro Independencia to 49%. But Wirth was clear - they're still in "debt recovery mode" and expect Venezuela to represent just 1-2% of cash flow from operations.

**ALEX:** The Q&A session had some really telling moments. When analysts pressed about capital allocation in this higher price environment, CFO Eimear Bonner was adamant about staying disciplined. No changes to their $2.5-3 billion quarterly buyback range.

**JORDAN:** That's smart. She said it's too early - only eight weeks into the conflict - to fundamentally change their outlook. They're not being pro-cyclical on buybacks, which shows real capital discipline.

**ALEX:** One of the more intriguing discussions was about their exclusive negotiations with Microsoft for power projects. Wirth mentioned they're advancing a West Texas project and could reach FID later this year. That's Chevron diversifying into the data center power space.

**JORDAN:** The timing there is interesting too. With AI driving massive power demand and Microsoft being their cloud provider, this feels like a natural partnership. Wirth seemed confident they could align Microsoft's power price expectations with Chevron's

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the latest quarterly results and what they mean for investors. I'm Alex.

**JORDAN**: And I'm Jordan. Today we're breaking down Colgate-Palmolive's Q1 2026 earnings call, and there's quite a bit to unpack here.

**ALEX**: Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Absolutely. Now, Alex, Colgate had an interesting quarter - some really strong performance in certain areas, but they're also dealing with significant headwinds. Where do you want to start?

**ALEX**: Let's kick off with the headline numbers. Colgate delivered what CEO Noel Wallace called "strong top and bottom line growth" with organic sales growth actually accelerating from Q4. They saw growth in both volume and pricing across all four categories and four of five divisions, which is pretty impressive breadth.

**JORDAN**: That's right, and what really caught my attention was the geographic mix. Emerging markets were the star of the show, particularly Asia Pacific. Wallace mentioned that these are regions where Colgate's global brands have higher market shares and greater scale advantages, so they're doubling down on investments there.

**ALEX**: Speaking of investments, they're maintaining their focus on brand equity and advertising spending, which is notable given the cost pressures they're facing. But Jordan, let's talk about the elephant in the room - that $300 million increase in expected raw material and logistics costs.

**JORDAN**: Yeah, this is where things get interesting from a margins perspective. They had to revise their gross margin outlook downward because of these cost pressures. CFO Stanley Sutula broke it down - about two-thirds of that $300 million hit is from raw materials, one-third from logistics. The big culprits? Oil byproducts like resins and petrochemicals, with spending in those areas expected to be up more than 20% year-over-year.

**ALEX**: And they're assuming crude oil at around $110 for their planning purposes. But here's what I found encouraging - despite these headwinds, they reaffirmed their full-year guidance for both top and bottom line growth. How are they managing to do that?

**JORDAN**: It comes down to what Wallace calls their "flexible P&L model." They're offsetting these cost pressures through several levers: revenue growth management, or RGM, productivity initiatives, and they just announced an acceleration of their Strategic Growth and Productivity Program - or SGPP.

**ALEX**: Let's dig into that SGPP announcement because it's pretty significant. They're now targeting $200 million to $300 million in annualized savings, with most of those savings hitting in 2027 and 2028. Wallace emphasized this isn't an extension of the program - it's still completing by end of 2028 - but they've identified additional opportunities.

**JORDAN**: Right, and Sutula explained that the strong execution from their teams allowed them to reach the high end of their initial targets, plus they found new ways to simplify operations and enhance efficiency. I like that they're being proactive about organizational structure and reducing complexity.

**ALEX**: Now, the regional performance was really telling. Asia Pacific was a standout, with improvements in both China through their Hawley & Hazel business and strong performance in India. Wallace mentioned they're not "completely out of the woods" in China yet, but the interventions they've made - accelerated innovation, better omnichannel execution - are starting to pay off.

**JORDAN**: Latin America also had another strong volume quarter with mid-single-digit growth. Wallace was particularly enthusiast

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and joining me as always is my co-host Jordan. Today we're diving into Cigna Group's Q1 2026 earnings call - and wow, there's a lot to unpack here, including some major leadership changes and strategic pivots.

But before we jump in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Thanks Alex. And speaking of major changes, this earnings call was pretty historic - it was CEO David Cordani's final quarterly call after 17 years leading the company. But the numbers certainly gave him a strong send-off.

ALEX: Absolutely! So let's start with the headline numbers. Cigna reported Q1 revenue of $68.5 billion and adjusted EPS of $7.79. That EPS represents 16% year-over-year growth, which is pretty impressive. And based on this strong performance, they raised their full-year 2026 EPS guidance to at least $30.35.

JORDAN: What's interesting is that both of their main segments - Evernorth and Cigna Healthcare - performed above internal expectations. Evernorth earnings were slightly ahead, while Cigna Healthcare really exceeded expectations with 18% earnings growth year-over-year. The medical care ratio came in at 79.8%, which was better than their guidance of slightly below 81%.

ALEX: Now Jordan, there were some significant strategic announcements that I think investors need to pay attention to. Can you walk us through those?

JORDAN: Sure thing. Cigna made two big portfolio moves. First, they're planning to exit the individual exchange business at the end of 2026. This isn't a huge surprise - it's been a small and shrinking business for them. CEO-elect Brian Evanko said they couldn't see a clear path to scale it meaningfully within Cigna's overall size.

The second move is potentially bigger - they announced a strategic review for eviCore, which handles prior authorization services for multiple health plans. This seems to be driven by the industry's progress on standardizing and automating prior authorization processes.

ALEX: And these moves really fit into their broader strategy of portfolio shaping, right? They're focusing resources on their three core growth platforms.

JORDAN: Exactly. Evanko outlined those three platforms clearly: Specialty and Care Services, which represents about 35% of company income and is growing 8-12% annually; Pharmacy Benefit Services at about 25% of income; and Cigna Healthcare at 40% of income. They're essentially doubling down on what's working and shedding what isn't.

ALEX: Let's talk about that specialty business because it really shone this quarter. Specialty and Care Services earnings grew 20% to $1.1 billion. What's driving that?

JORDAN: Three main factors. First, solid specialty volume growth across the board. Second - and this is interesting - continued adoption of biosimilars and specialty generics. These deliver savings to patients while actually improving margins for Cigna. Third, they're getting contributions from their investment in Shields Health Solutions, which they made late last year.

David Cordani specifically highlighted how they're using AI to improve biosimilar conversions. For drugs like Humira and Stelara, they're offering $0 out-of-pocket costs to patients while using AI to identify personalized conversion strategies. It's a win-win - lower costs, higher patient satisfaction, and better margins.

ALEX: That ties into something Brian Evanko emphasized about the future - this focus on AI and data analytics. He's clearly putting his stamp on the company's direction.

JORDAN: Right. When he takes over as CEO in July, Evanko outlined three areas of intensification: better use of data and AI for personalized care, drivin

This episode includes AI-generated content.

**Beta Finch Podcast Script - Stryker Q1 2026 Earnings**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from corporate America's quarterly reports. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Stryker's Q1 2026 results, and wow, this was definitely not your typical earnings call.

**ALEX:** Before we get into it, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely. So Alex, let's start with the elephant in the room - Stryker got hit by a cyberattack late in Q1. How bad was the damage?

**ALEX:** It was significant, Jordan. Organic sales growth came in at just 2.4% - way below what you'd normally expect from Stryker. Even more telling, adjusted earnings per share dropped 8.5% to $2.60. CEO Kevin Lobo mentioned they had 40,000 laptops wiped and were essentially shut down for about three weeks.

**JORDAN:** That's brutal. But here's what caught my attention - despite all this chaos, they maintained their full-year guidance. That's either incredibly optimistic or they have serious confidence in their recovery plan.

**ALEX:** I'm leaning toward confidence. CFO Preston Wells was pretty detailed about why they think they'll bounce back. He explained that different business units were affected differently based on their operating models. For example, their orthopedic business has a lot of consigned inventory sitting right at hospitals, so surgeries could continue even when Stryker's systems were down.

**JORDAN:** Right, it was more of a revenue recognition issue there rather than lost procedures. But their capital equipment business - things like hospital beds and defibrillators - that's where they really got hit because those are made-to-order products.

**ALEX:** Exactly. And Wells said most of that lost production will shift to Q3 and Q4 rather than Q2, which makes sense given manufacturing lead times. What I found interesting was how resilient their underlying business seems to be.

**JORDAN:** Talk about that resilience - what are the bright spots?

**ALEX:** Well, they had their best-ever Q1 for Mako robot installations, both in the US and internationally. That's their surgical robotics platform, and utilization rates are climbing. Plus they just got European approval for Pangaea - that's their trauma plating system that's been driving explosive growth in the US.

**JORDAN:** And let's not forget the M&A activity. They announced they're acquiring Amplitude Vascular Systems, which gets them into the intravascular lithotripsy space. That's basically using sound waves to break up calcified plaque in blood vessels.

**ALEX:** Kevin Lobo was really bullish on that deal during the Q&A. He said it fits perfectly with their existing peripheral vascular business through Inari, which they bought last year. Same call points, same physicians.

**JORDAN:** Speaking of the Q&A, there were some great nuggets in there. One analyst asked about competitive dynamics in orthopedics, and Lobo basically said "bring it on." He mentioned they expect to keep outgrowing the orthopedic market by 200 to 300 basis points, just like they have been.

**ALEX:** I loved his comment about their robotics portfolio too. He said the new Mako RPS - that's their handheld robotic system - is getting great feedback, especially in ambulatory surgery centers. It's like a stepping stone for surgeons who find full Mako too intimidating.

**JORDAN:** The international story is pretty compelling too. While the US grew 1.9%, international was up 3.9% despite the cyber issues. Lobo highlighted Japan as their second-largest market outside the US, and it's experiencing "tremendous growth."

**ALEX:** And they're just getting

This episode includes AI-generated content.

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the numbers that move markets. I'm Alex, and joining me as always is Jordan. Today we're breaking down Apple's Q2 2026 earnings – and folks, this wasn't just any ordinary quarter. Jordan, before we jump in, I need to share our disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex, and wow – where do we even start with this Apple quarter? I mean, we've got blockbuster numbers AND a major leadership transition announcement all in one call.

**ALEX**: Right? Tim Cook announcing he's stepping down as CEO after 15 years to become Executive Chairman, with John Ternus taking over in September. But let's start with the financial fireworks. Apple absolutely crushed it with $111.2 billion in revenue – that's up 17% year-over-year and a March quarter record.

**JORDAN**: And that revenue beat came despite supply constraints, which is remarkable. iPhone was the star of the show at $57 billion, up 22% year-over-year. Alex, when you're supply constrained and still growing at over 20%, that tells you something about the underlying demand strength.

**ALEX**: Absolutely. And it wasn't just iPhone – they had double-digit growth across every geographic segment, including Greater China which grew 28% and hit a quarterly record. The iPhone 17 family seems to be resonating incredibly well with customers.

**JORDAN**: Let's talk about those supply constraints because this is fascinating from an operational perspective. Cook was pretty transparent about this – the main constraint is availability of advanced nodes for their SoCs, not memory as some might have expected. And get this – for Mac specifically, they're seeing higher than expected demand for Mac mini and Mac Studio because customers are recognizing these as powerful AI platforms.

**ALEX**: And don't forget the MacBook Neo! Cook said customer response has been "off the charts" with higher than expected demand. They set a March record for customers new to Mac, partly due to the Neo. It sounds like Apple's strategy of bringing Mac to more people at a breakthrough price is really working.

**JORDAN**: Services hit another all-time record at $31 billion, up 16%. But here's what caught my attention – they announced they're ending their formal net cash neutrality target. CFO Kevan Parekh said they want more flexibility to evaluate cash and debt independently.

**ALEX**: That's a big strategic shift. They authorized another $100 billion in share buybacks and raised the dividend 4% to 27 cents per share. It sounds like they want more financial flexibility as they ramp up AI investments, which brings us to the elephant in the room – their AI strategy.

**JORDAN**: Cook was asked about agentic AI and the future of smartphones, and while he didn't reveal future products, he emphasized how thrilled they are with Apple Intelligence integration. The company is clearly investing heavily – R&D spending is accelerating much higher than overall company growth.

**ALEX**: The memory cost situation is interesting though. Cook was pretty direct about this – they expect "significantly higher memory costs" in the June quarter and said beyond that, memory costs will drive "an increasing impact" on their business. When analysts pushed on margins, he said they'll "look at a range of options."

**JORDAN**: That's code for potential pricing actions, right? With 99% customer satisfaction on the iPhone 17 family in the US, they clearly have pricing power. But Cook was coy about whether they'd focus on market share gains or profitability in this cost environment.

**ALEX**: Let's talk about the guidance. They're expecting total company revenue to grow 14% to 17% year-over-year in June, which assumes co

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

**JORDAN**: And I'm Jordan. Today we're diving into Southern Company's Q1 2026 earnings call, and wow - this utility is absolutely crushing it in the data center boom.

**ALEX**: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Absolutely. So Alex, let's start with the numbers because they're pretty impressive.

**ALEX**: They really are. Southern posted adjusted earnings per share of $1.32 for Q1, which was 9 cents higher than last year and beat their own estimate by 12 cents. That's solid execution right there.

**JORDAN**: What's driving this outperformance? Because utilities aren't exactly known for big earnings surprises.

**ALEX**: Here's where it gets interesting - it's all about load growth. Their weather-normal retail electricity sales jumped 2.3% year-over-year, which CEO Chris Womack called "the highest total retail sales growth that we have seen in the first quarter in recent history." But the real story is in the commercial segment.

**JORDAN**: Right, commercial sales were up 4.5% when adjusted for weather, and get this - data center usage alone was up 42% year-over-year. That's not a typo, folks. Forty-two percent.

**ALEX**: And they added 46,000 new residential customers to their system. The Southeast continues to be this massive economic magnet. In Q1 alone, they announced over $7 billion in capital investment and nearly 4,000 permanent jobs coming to their region.

**JORDAN**: The scale of what Southern is dealing with on the large load front is just staggering. They now have 11 gigawatts of fully contracted large load agreements - that's enough to power roughly 8 million homes. And in just the last two months, they signed contracts for another 1.9 gigawatts with hyperscalers.

**ALEX**: But here's what I love about their approach - these aren't your typical utility contracts. Every single large load customer has to cover their full share of costs to serve them. There are minimum bills, collateral requirements, cancellation fees. Southern isn't taking any risks here.

**JORDAN**: Smart structure. And the pipeline is enormous - they're talking about over 75 gigawatts in their prospective pipeline, with 12 gigawatts in late-stage discussions through the mid-2030s. Half of that 12 gigawatts is expected to be finalized with executed contracts in the near term.

**ALEX**: To put that in perspective, Jordan, Southern's entire current generating capacity is around 50 gigawatts. We're potentially talking about doubling their system over the next decade.

**JORDAN**: Which brings us to the infrastructure challenge. Georgia Power just launched an RFP - that's request for proposals - for 2 to 6 gigawatts of new dispatchable generation, including thermal, battery storage, and renewables, all coming online in 2032-2033.

**ALEX**: And they're not just planning - they're already building. They've got 10 gigawatts of new generation resources under development right now. Georgia Power just brought two new battery storage systems online, totaling nearly 200 megawatts of capacity.

**JORDAN**: The financial implications are massive too. CFO David Poroch mentioned that if they get selected for company-owned resources in these RFPs, we could be looking at about $2 billion of incremental capital expenditure per gigawatt. That's serious money.

**ALEX**: Speaking of money, they just secured something pretty remarkable - $26.5 billion in loan agreements with the Department of Energy. This is historic low-cost financing that's projected to save customers $7 billion over the 30-year term.

**JORDAN**: That's huge for their capital structure. It reduces their reli

This episode includes AI-generated content.

# Beta Finch Podcast Script: Merck Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Merck's Q1 2026 results, and wow - there's a lot to unpack here.

**JORDAN:** That's right, Alex. And before we jump in, I need to share our standard disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX:** Thanks, Jordan. Now, let's talk about the headline numbers. Merck reported revenue of $16.3 billion for Q1, which represents 5% growth year-over-year, or 3% excluding foreign exchange impacts. But here's the kicker - they actually posted a loss of $1.28 per share.

**JORDAN:** Right, and that loss is entirely due to a massive one-time charge. Merck took a $9 billion hit related to their acquisition of Cidara Therapeutics. Without that charge, they would have been profitable. In fact, they raised their full-year guidance, which tells you management feels pretty good about the underlying business.

**ALEX:** Exactly. They bumped up their revenue guidance to between $65.8 billion and $67 billion for the full year, and raised their EPS guidance to $5.04 to $5.16. But Jordan, let's talk about what's really driving this growth - because it's not just KEYTRUDA anymore.

**JORDAN:** That's the big story here, Alex. Yes, KEYTRUDA sales were still strong at $8 billion, up 8%, but what caught my attention was how diversified their growth drivers are becoming. WINREVAIR, their pulmonary arterial hypertension drug, hit $525 million in sales. That's a relatively new product showing real traction.

**ALEX:** And then there's WELIREG, their oral HIF-2-alpha inhibitor, which saw 43% growth to $199 million. Management highlighted they have over 20 new products launching with what they called "blockbuster potential." CEO Rob Davis mentioned a potential commercial opportunity of over $70 billion by the mid-2030s from these new growth drivers alone.

**JORDAN:** Those are big numbers, Alex. But let's talk about some challenges too. GARDASIL sales dropped 22% to $1.1 billion, mainly due to lower demand in China and Japan. And their new RSV prevention drug ENFLONSIA had minimal sales in Q1, though that was expected due to seasonality.

**ALEX:** True, but management seemed confident about the RSV product ramping up in the second half of the year. What really stood out to me from the call was their focus on AI and partnerships. They announced a multi-year deal with Google Cloud for AI capabilities, plus expanded collaborations with Tempus AI and the Mayo Clinic.

**JORDAN:** That's a smart move, especially in drug development where AI could potentially accelerate research timelines. Speaking of their pipeline, they had some interesting updates. The FDA approved their HIV drug IDVYNSO, and they're expecting several priority reviews in the coming months for cancer treatments.

**ALEX:** The pipeline discussion was fascinating. Dr. Dean Li, their research chief, mentioned they have 17 Phase III studies ongoing for their antibody-drug conjugate sac-TMT, with 13 of those in "first mover" indications. That could be huge if those trials are successful.

**JORDAN:** And let's not forget the Terns Pharmaceutical acquisition they're working on. They're paying about $5.8 billion for TERN-701, a chronic myeloid leukemia drug candidate. Management thinks it has "multibillion-dollar commercial potential."

**ALEX:** During the Q&A, analysts were clearly focused on the pipeline readouts coming this year. There was a lot of discussion about their ophthalmology programs and cancer combination therapies. One thing that struck me was how confident management sounded about their diversification strategy.

**JORDAN:** Absolutely. CFO Caroline Litchfield mentioned

This episode includes AI-generated content.